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Summary
 
The orphan receptor CRF2-4 is a member of the class II cytokine receptor family (CRF2),
which includes the interferon receptors, the interleukin (IL) 10 receptor, and tissue factor.
CRFB4, the gene encoding CRF2-4, is located within a gene cluster on human chromosome
21 that comprises three interferon receptor subunits. To elucidate the role of CRF2-4, we dis-
rupted the CRFB4 gene in mice by means of homologous recombination. Mice lacking
CRF2-4 show no overt abnormalities, grow normally, and are fertile. CRF2-4 deficient cells
are normally responsive to type I and type II interferons, but lack responsiveness to IL-10. By
 
z
 
12 wk of age, the majority of mutant mice raised in a conventional facility developed a
chronic colitis and splenomegaly. Thus, CRFB4 mutant mice recapitulate the phenotype of
IL-10–deficient mice. These findings suggest that CRF2-4 is essential for IL-10–mediated ef-
fects and is a subunit of the IL-10 receptor.
 
T
 
he class II cytokine receptor family (CRF2)
 
1
 
 has been
defined on the basis of significant sequence and struc-
tural resemblance, notably evolutionary links to fibronectin
type III within domains of the extracellular receptor por-
tion of 
 
z
 
100 amino acids (1). The family includes tissue
factor (TF; 2, 3), a ligand-binding subunit of the IL-10 re-
ceptor (IL-10R1; 4, 5), two subunits of the IFN-
 
g
 
 receptor
(IFN-
 
g
 
R1 and IFN-
 
g
 
R2; 6–8), two subunits of the IFN-
 
a
 
receptor (IFN-
 
a
 
R1 and IFNAR2; 9–11), and the orphan
receptor CRF2-4 (12, 13). CRF2 members are character-
ized by the presence of a 200–amino acid extracellular do-
main composed of two distinct subdomains of 100 amino
acids (1). These subdomains contain conserved cysteine, pro-
line, and tryptophan residues that determine a characteristic
folding pattern of seven beta strands similar to the constant
domain of immunoglobulins (14). Family members also con-
tain conserved intracellular domain regions that are in-
volved in the interaction with downstream signaling mole-
cules (15).
Full length CRFB4 (the gene that encodes CRF2-4)
cDNA was cloned based on an expressed sequence tag cor-
responding to the D21S58 locus on human chromosome
21 that maps close to IFNAR1 (12, 16). The genes encod-
ing IFN-
 
a
 
R2, CRF2-4, IFN-
 
a
 
R1, and IFN-
 
g
 
R2 form a
cluster on human chromosome 21 (11). Human CRFB4
cDNA was also independently cloned through exon trap-
ping and used as a probe to isolate a murine homologue
that encodes a 349–amino acid polypeptide that is 69%
identical to the 325-residue human counterpart (13).
CRFB4 maps on chromosome 16 to a region of conserved
synteny with human chromosome 21 (16). This clustering
and the similarity to IFN receptor genes (17) suggested that
CRF2-4 may be a component of IFN receptors, but coex-
pression of human CRF2-4 with human IFN-
 
a
 
R1 and/or
human IFN-
 
a
 
R2 in a mouse L929 cell line did not affect
the responsiveness of such cells to human IFNs (Gibbs,
V.C., unpublished data).
Whereas functional type I and type II IFN receptors
have been reconstituted from their known subunits (14,
18), there is evidence to suggest that other CRF2 members
may need additional receptor subunits to transduce biolog-
ical responses.
TF is a high affinity receptor for plasma factor VII/VIIa
and is responsible for cellular initiation of the coagulation
protease cascade (2). There is evidence to suggest that TF
that has only a 20–amino acid cytoplasmic domain may
participate in intracellular signaling through association
with an unknown coreceptor. Thus, inactivation of the TF
gene in the mouse resulted in early embryonic lethality,
 
1
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presumably due to anomalies in blood vessel formation (19,
20). There is some biochemical evidence to suggest that, in
monocytes, TF may associate with a component of the IgE
receptor (21), but TF-mediated signaling pathways remain
elusive.
IL-10R1 is able to bind IL-10 and signal a biological re-
sponse, but there is evidence to suggest that a coreceptor is
involved. Intriguingly, human IL-10 proved more active
on mouse Ba/F3 cells transfected with the murine IL-
10R1 than on the same cells expressing the human IL-
10R1 (5), suggesting that these murine cells may express a
species-specific coreceptor. Characterization of an EBV-
derived IL-10 homologous protein (22) provided further
evidence for the requirement of additional receptor com-
ponents for signaling. Notably, a soluble form of human
IL-10R1 neutralized biologic responses only to human, but
not to EBV-derived, IL-10 (5). Lastly, IL-10 treatment of
T cells and monocytes triggers activation of the Jak1 and
Tyk2 kinases (23, 24). The known receptor subunit copre-
cipitated only with Jak1, suggesting that Tyk2 may associ-
ate with a second receptor subunit (23, 24). Using hybrid
IFN-
 
g
 
R2/CRF2-4 molecules, it has recently been shown
that CRF2-4 associates with Tyk2 (25), and it was pro-
posed that CRF2-4 may be a subunit of the IL-10R (26).
To clarify whether CRF2-4 may be a coreceptor of
other CRF2 members, we generated mice with an inacti-
vated CRFB4 gene.
 
Materials and Methods
 
Generation of CRFB4
 
2
 
/
 
2
 
 Embryonic Stem Cells and Mice.
 
A
 
32
 
P-labeled oligonucleotide derived from exon II of murine
CRFB4 was used to screen an isogenic 129Sv/Ev embryonic stem
(ES) cell library (27). A clone containing an 18-kb gene fragment
encoding exons I–V of CRFB4 was identified and subcloned into
a Bluescript vector as four SacI fragments. To generate the
CRFB4 targeting vector, a 5.0-kb ClaI fragment containing ex-
ons III and IV was placed into the ClaI site of the pTK.neo.ums
vector (28) such that its 3
 
9
 
 end was adjacent to the polyoma en-
hancer promoter-driven herpes simplex virus thymidine kinase
gene. The 5
 
9
 
 end of the targeting construct was generated by in-
serting a 2.0-kb EcoRI fragment containing sequences upstream
of exon I into the blunted NotI site of the pTK.neo.ums (see Fig.
1). ES-D3 mouse ES cells were cultured in high glucose DME
with 10% FCS and leukemia inhibitory factor (LIF) on mouse
embryonic feeder cells. ES cells were electroporated with 10 
 
m
 
g
of SstI linearized CRFB4 targeting vector per 10
 
7
 
 cells and grown
under double selection in 400 
 
m
 
g/ml G-418 and 1 
 
m
 
M gancyclo-
vir (Roche Labs., Nutley, NJ). Cells were analyzed for homolo-
gous recombination by Southern blot analysis as previously de-
scribed (29). Genomic DNA was digested with SpeI and the
disrupted allele was detected by hybridization with a 
 
32
 
P-labeled 1.3-
kb XbaI fragment derived from genomic sequences upstream of
the targeting vector. 3 positive clones were identified by the pres-
ence of a 5-kb SpeI fragment in addition to the 15-kb SpeI band
typical of the CRFB4 wild-type allele. To generate ES cells with
a homozygous mutation of the CRFB4 gene, ES cells carrying
the CRFB4
 
1
 
/
 
2
 
 mutation were cultured in high concentrations of
G-418 as described (30). CRFB4
 
1
 
/
 
2
 
 ES cells were injected into
C57Bl/6 blastocysts and resulting male chimeras mated to
C57Bl/6 females. CRFB4
 
1
 
/
 
2
 
 offspring were intercrossed to gen-
erate homozygous mutant mice. Mutant mice were kept in con-
ventional animal facilities.
 
Macrophage Cell Culture and IL-10 Bioassay.
 
Biological activ-
ity of IL-10 was determined by its ability to inhibit LPS-stimu-
lated TNF-
 
a
 
 production in macrophages isolated from bone
marrow as previously described (31, 32). In brief, bone marrow–
derived macrophages were obtained by culturing 10
 
7
 
 bone mar-
row cells in 50 ml of high glucose DME containing 20% inacti-
vated horse serum, 4 mM 
 
l
 
-glutamine, 1 mM sodium pyruvate,
50 U/ml of penicillin, and 50 
 
m
 
g/ml of streptomycin, and sup-
plemented with 30% (v/v) L929-conditioned medium in bacte-
rial culture 10 mm Petri dishes for 7 d. Adherent cells were re-
seeded in 96-well plates at a density of 5 
 
3
 
 10
 
4
 
 cells/well. IL-10
was added at various concentrations and cells were incubated for
1 h at 37
 
8
 
C before the addition of 50 ng LPS. Incubation was
continued for 24 h at 37
 
8
 
C, and culture supernatants were assayed
for TNF-
 
a
 
 activity as previously described (33).
 
Activation of IFN-inducible Genes and Northern Blot Analysis.
 
Wild-type and CRFB4
 
2
 
/
 
2
 
 ES cell lines were allowed to differen-
tiate by growth on gelatin in the absence of LIF for 10 d. Differ-
entiated ES cells were treated for 4 h with 1 
 
m
 
g/ml of murine
IFN-
 
g
 
 or 1,000 U/ml of recombinant human IFN-
 
a
 
2/
 
a
 
1, which
is cross-reactive on mouse cells (34). Northern analysis was per-
formed on 10 
 
m
 
g total RNA loaded per lane. Probes were as fol-
lows: a 1.9-kb EcoRI fragment encoding murine IFN regulatory
factor 1 (35); a 1.2-kb PCR fragment containing nucleotide 51–
1240 of murine PKR (double stranded RNA-dependent protein
kinase) (36), derived by reverse transcriptase PCR from RNA of
IFN-treated L929 cells; a 0.9-kb fragment containing nucleotide
71–949 of murine 2,5-A oligoadenylate synthetase (37), derived
by reverse transcriptase PCR from RNA of IFN-treated L929
cells; a 1 kb XbaI-HindIII fragment derived from plasmid
pRK.muCRFB4 containing the open reading frame of CRF2-4;
and a 0.5-kb XhoII fragment of the GAPDH (glutaraldehyde
3-phosphate dehydrogenase) gene (38).
 
Flow Cytometry.
 
Single-cell suspensions from thymocytes,
spleen cells, and peritoneal cells were isolated from 15–21-wk-old
mice, resuspended in PBS and incubated with the appropriate
mAbs, for 1 h at 4
 
8
 
C. In most experiments, splenocytes and peri-
toneal cells were preincubated with purified rat IgG anti–mouse
CD16/CD32 mAb (Fc Block; PharMingen, San Diego, CA) that
blocked the nonspecific adherence of subsequent antibodies to
murine Fc receptors. The following mAbs were purchased from
PharMingen, except where designated, and were used in flow cy-
tometric analysis: biotin-conjugated anti-CD90.2 (Thy-1.2; clone
53-2.1); FITC-conjugated anti-CD4 (clone YTS 177.9; Serotec
Ltd., Kidlington, Oxford, UK); PE-conjugated anti-CD8a (Ly-2;
clone 53-6.7); biotin-conjugated anti-CD19 (clone 1D3); FITC-
conjugated anti-CD45R/B220 (clone RA3-6B2); biotin-conju-
gated anti-IgM (clone R6-60.2); FITC-conjugated anti-IgD (clone
11-26c.2a); FITC-conjugated anti-CD11b (Mac 1; clone M1/70;
Serotec Ltd.); PE-conjugated anti-CD5 (Ly-1; clone 53-7.3);
PE-conjugated anti-CD24 (heat stable antigen; clone M1/69);
anti-H-2Kb (clone E121.46; Seikagaku Corporation, Rockville,
MD); and PE-conjugated anti-I-a (clone MRC OX-3; Serotec
Ltd.). Biotinylated mAbs were detected in a second staining step
with streptavidin-PE or streptavidin-FITC. Unconjugated mAbs
were detected with PE- or FITC-labeled goat anti–mouse IgG
antisera (Caltag Antibodies, South San Francisco, CA). Cells were
analyzed with a FACScan
 
Ò
 
 cytometer and Cellquest software
(Becton Dickinson, San Jose, CA). Dead cells were excluded by
propidium iodide staining. Cells present in the lymphocyte or
 573
 
Spencer et al.
monocyte gate as defined by forward light scatter were analyzed.
In stimulation experiments, thymocytes or splenocytes were iso-
lated and cultured for 20 h in microtiter plates in the presence
or absence of various concentrations of IFN-
 
a
 
, IFN-
 
g
 
, IL-4, IL-
10, or LPS. Cells were harvested and washed once with PBS and
then incubated with the indicated antibodies and analyzed by
flow cytometry.
 
Histopathology.
 
Mice were killed by asphyxiation and com-
plete necropsy was performed. Terminal body weight, absolute
organ weights, and organ to body weight ratios were determined.
Blood samples collected in EDTA were analyzed on a Technicon
H1E Analyzer (Bayer Diagnostics Division, Tarrytown, NY) ac-
cording to the manufacturer’s instructions. Tissues were fixed
with buffered 1% glutaraldehyde, 4% paraformaldehyde, then
embedded in plastic and 2-
 
m
 
m-thick sections were stained with
Giemsa.
 
Results
 
Generation of CRF2-4–deficient ES Cells and Mice.
 
The
CRFB4 gene was inactivated by transfecting ES cells with a
replacement vector containing 7 kb of the murine gene
(Fig. 1 
 
A
 
). Homologous integration resulted in the replace-
ment with the neomycin resistance gene of exons I and II
of the CRFB4 gene, which encode the first 39 amino acid
residues of the protein, including the signal peptide. The
structure of the mutated CRFB4 gene in targeted ES cells
and in the progeny of germline chimeras was identified by
Southern blot analysis (Fig. 1 
 
B
 
). Homologous recombina-
tion occurred with a frequency of 1 in 180 G-418 and
Gancyclovir-resistant ES cell colonies. Homozygous mu-
tant clones were obtained in high G-418 concentrations as
previously described (30). Northern blot analysis confirmed
the disruption of the CRFB4 gene as evidenced by the ab-
sence of the 2.4-kb CRF2-4 mRNA (Fig. 1 
 
C
 
). Homozy-
gous CRFB4 mutant mice were obtained from three inde-
pendent heterozygous ES cell clones with a Mendelian
frequency, proved fertile, and had no apparent phenotypic
anomalies by 12 mo of age. Gross anatomical examination
revealed no phenotypic differences except for macroscopic
signs of colitis and splenomegaly in a majority of mutant
mice. CRFB4
 
2
 
/
 
2
 
 mice housed in a conventional facility
were fertile but had poor reproductive success, presumably
due to disease development (see below).
 
CRFB4
 
2
 
/
 
2
 
 Cells Respond Normally to IFN-
 
a
 
 and IFN-
 
g
 
.
 
To address the possibility that CRF2-4 may have a role in
interferon signaling, the biological responses of CRFB4
 
2
 
/
 
2
 
ES cells to IFN-
 
a
 
 and IFN-
 
g
 
 were examined. As ES cells
constitutively express some IFN-dependent genes, such as
IRF-1 (39), CRFB4
 
2
 
/
 
2
 
 and control ES cells were cultured
for 10 d in the absence of LIF on gelatin-coated plates to
induce fibroblastoid differentiation and were then either
left untreated or incubated with IFN-
 
a
 
 or IFN-
 
g
 
. Total
RNA was isolated and subjected to Northern blot analysis
using probes derived from several IFN-inducible genes as
indicated (Fig. 2, 
 
A–C
 
). No significant differences were
observed in the responses of CRFB4
 
2
 
/
 
2
 
 versus wild-type
cells. Next, we examined the ability of IFN-
 
a
 
 and IFN-
 
g
 
to upregulate expression of MHC class I antigen on thy-
mocytes. Cells from either normal or mutant mice had
comparable basal MHC class I antigen levels and responded
to a similar extent to either IFN-
 
a
 
 or IFN-
 
g
 
 (data not
shown).
 
Macrophages and Lymphocytes from CRFB4
 
2
 
/
 
2
 
 Mice are
Unresponsive to IL-10.
 
To assess whether the IL-10 system
was affected by the lack of CRF2-4, IL-10 responsiveness
was assayed on bone marrow–derived macrophages as pre-
viously described (31, 32). The ability of IL-10 to inhibit
LPS-stimulated production of TNF-
 
a
 
 (31) was lost in bone
marrow–derived macrophages from CRFB4
 
2
 
/
 
2
 
 mice (Fig. 3
 
A
 
). Likewise, the ability of IL-10 to induce Fc
 
g
 
III/II recep-
tor expression on lymphocytes and monocytes (40) was abol-
ished in cells derived from CRFB4
 
2
 
/
 
2
 
 mice (Fig. 3 
 
B
 
).
 
Cytofluorometry.
 
To address the possibility that inactiva-
tion of the CRFB4 gene may affect other immune func-
tions, thymocytes, splenocytes, and peritoneal cells from
unchallenged 13–21-wk-old mutant and control mice were
subjected to cytofluorimetric analysis. At these time points
the T cell compartment in the thymus and spleen was sim-
ilar in mutant and wild-type mice. Therefore, CRF2-4 is
not essential for the generation of CD4
 
1
 
 and CD8
 
1
 
 T cells
(data not shown). CRFB4
 
2
 
/
 
2
 
 mice consistently had in-
Figure 1. (A) The structure of the murine gene was predicted from the
published human gene (17). Exons (black boxes) are numbered I–IV. The
targeting vector was designed to replace exons I and II with the neomycin
resistance gene. Homologous insertion of the targeting vector resulted in
the introduction of an additional SpeI site (S). (B) Southern blot analysis
of SpeI-digested ES cell DNA. Probe: 1.3-kb XbaI fragment derived
from genomic sequences upstream of the targeting vector. (C) Northern
blot of total RNA derived from wild-type or CRFB42/2 ES cells probed
with a 1 kb XbaI-HindIII random labeled fragment derived from murine
CRFB4 cDNA.
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creased numbers of splenocytes, due to an expansion of
CD11b, Mac1-positive polymorphonuclear, monocytic cells.
IgM/IgD-expressing B cells and CD51 (Ly-1) B cells were
similar in mutant and control mice. There were slightly
fewer MHC class II positive B cells in CRFB42/2 mice
than in control mice, but IL-4 treatment of splenocytes in-
creased expression of MHC class II antigens in all CD191 cells
to a similar extent in both the wild-type and CRFB42/2
cells. Serum IgG, IgM, and IgA, was not significantly dif-
ferent in wild-type and mutant mice (data not shown).
Peritoneal cells in CRFB42/2 mice were also composed of
a higher percentage of CD11b1 cells than in wild-type lit-
termates.
CRFB42/2 Mice Develop Splenomegaly and Colitis. Histo-
pathological examination was performed on two groups of
mice. The brain, heart, kidney, thymus, pancreas, and re-
productive organs from CRF2/2 mice that had been kept
in a conventional animal facility were grossly and histologi-
cally normal. In contrast, marked alterations were present
in the large intestine, spleen, and the hematopoietic system.
There was thickening and narrowing of the large intestine
in CRFB42/2 mice relative to wild-type littermate controls,
and there was a fourfold increase in the spleen/body weight
ratio. The splenomegaly was correlated with a dramatic in-
crease in extramedullary hematopoiesis in the splenic red
pulp involving erythroid, myeloid, and megakaryocytic lin-
eages. There was mesenteric lymphadenopathy with an in-
Figure 2. Northern blot analysis of IFN-inducible genes. Wild-type
(lanes 1–3) or CRFB42/2 ES cells (lanes 4–6) were cultured under differ-
entiating conditions and treated for 4 h at 378C with 1,000 U/ml IFN-
a2/a1 (lanes 2 and 5), 1 mg/ml muIFNg (lanes 3 and 6; Genentech, Inc.,
South San Francisco, CA) or left untreated (lanes 1 and 4). Northern blot
analysis was carried out with 10 mg of total RNA per lane and blots were hy-
bridized as indicated with the probes described in Materials and Methods.
Figure 3. Macrophages and splenocytes derived from CRFB42/2 mice
are unresponsive to IL-10. (A) TNF production in LPS-activated mac-
rophages. Bone marrow macrophages from individual wild-type (wt), het-
erozygous (1/2), or homozygous mutant mice (2/2) were pretreated
with 100 ng of IL-10 (white bars) or left untreated (black bars) and subse-
quently stimulated with 50 ng/ml of LPS before determination of TNF
secretion. Indicated values are means 6 SD of duplicate wells from two
independent experiments. (B) 105 splenocytes or 5 3 104 peritoneal
monocytes from wild-type or CRF2-4–deficient mice were treated with
10 ng of IL-10 (bold solid line) or left untreated (dotted line) for 20 h at
378C. Cell surface expression of FcgIII/II receptor was determined by
flow cytometry with anti-FcgIII/II mAb as described in Materials and
Methods. The first peak of cells in the splenocyte population represents
cells that do not express FcgIII/II receptors.
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crease in plasma cells in the medullary cords and increased
granulocytopoiesis in the sternal bone marrow. These
changes were reflected in the peripheral hematology, which
showed a slightly decreased hemoglobin concentration and
a leukocytosis composed primarily of neutrophils and mono-
cytes. Platelet counts were normal. The microscopic find-
ings in the large intestine consisted of moderate to severe
diffuse chronic colitis characterized by a mixed inflamma-
tory cell mucosal inflammation (Fig. 4). The colonic mu-
cosa was diffusely thickened by the inflammatory cell infil-
trate, and in severe cases also by hyperplasia of the crypt
epithelium. There was no involvement of the small intes-
tine. Immunohistochemistry on the large intestine demon-
strated that the inflammatory cell infiltrate was composed
predominately of macrophages (histiocytes), neutrophils, and
T lymphocytes. The histopathological changes of chronic
colitis and splenomegaly in CRFB42/2 mice were variable.
In an examination of 4 15–20-wk-old CRFB42/2 mice
raised in the colony in Switzerland, only two of the mice
demonstrated this phenotype. Among 9 13–32-wk-old
CRFB42/2 mice examined from the colony in the United
States, 7 animals had splenomegaly and colitis. It is unclear
whether these differences represent solely environmental
differences or whether they reflect genetic heterogeneity
(129Sv/Ev 3 C57Bl/6 background).
Discussion
We report the phenotypic analysis of mice lacking the
orphan receptor CRF2-4. This study was initiated by the
observation that the CRFB4 gene is located within a gene
cluster comprising the genes encoding three known sub-
units of IFN receptors. Therefore, before the second sub-
units of the IFN-g (7, 8) and the type I IFN receptor (10,
11) were known, CRF2-4 was considered a candidate sub-
unit of IFN receptors. The discovery of these IFN receptor
components allowed it to reconstitute functional IFN re-
ceptors, and the role of CRF2-4 remained elusive.
The detailed elucidation of the events that link the liga-
tion of the IFN-gR to the Jak–STAT signaling pathway
(18) provides a paradigm for other cytokine receptors. The
IFN-gR consists of two subunits that presumably form a het-
erotetramer upon receptor ligation. The ligand-binding sub-
unit (IFN-gR1) confers signal specificity through binding
of the signal transducer Stat1and associates with the tyro-
sine kinase Jak1. The second obligatory subunit (IFN-gR2)
recruits Jak-2 into the ligated complex (18). The cytoplas-
mic domain of R2 can be replaced with the cytoplasmic
domain of CRF2-4 (25) and still form a functional recep-
tor, confirming that the Jak family kinases are redundant in
terms of signaling specificity, and indicating that CRF2-4,
like the IFN-gR1, may function as a coreceptor.
Clearly, CRF2-4 is not an obligatory component of the
IFN system. Wild-type ES cells cultured under conditions
that induce differentiation are responsive to both type I and
type II IFNs. ES cells that lack CRF2-4 showed normal re-
sponses to both type I and type II IFNs (Fig. 2). Likewise,
splenocytes from wild-type and mutant mice showed com-
parable type I and type II IFN-mediated induction of
MHC class I and II antigens, respectively (data not shown).
The absence of any overt phenotype in mutant mice was in
contrast to the severe phenotype observed in mice that lack
TF (19, 20). Thus, the phenotypic analysis of mice lacking
CRF2-4 focused on the IL-10 receptor system as the last
known member of the CRF2 (4).
Some recent findings pointed to a potential role of
CRF2-4 as a component of the IL-10R; CRF2-4 associ-
ates with Tyk-2 (25), and aside from the type I IFN recep-
tor (41) the IL-10R is the only CRF2 member that acti-
vates Tyk2 (23, 24). Most recently, IL-10R1 was shown to
associate with CRF2-4 to form a functional receptor (26).
Our study unequivocally identifies CRF2-4 as an obliga-
tory element of the IL-10 system. Bone marrow–derived
macrophages isolated from mice lacking CRF2-4 were un-
responsive to IL-10, which normally inhibits LPS-stimu-
lated production of TNF in those cells (Fig. 3 A). Likewise,
splenocytes and peritoneal cells derived from mutant mice
Figure 4. Histopathology of the large bowel from CRFB42/2 mice
and control wild-type littermates. In contrast to controls showing a nor-
mal histology (A), the colon of mutant mice contains foci of colitis with
mucosal inflammatory cell infiltrates composed of neutrophils, monocytes,
macrophages, and lymphocytes (B). Original magnification: 3450.
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were unable to upregulate FcgIII/II receptors in response
to IL-10 (Fig. 3 B). Lastly, mice lacking CRF2-4 devel-
oped an inflammatory bowel disease reminiscent of the one
seen in mice lacking IL-10 (42, 43; Fig. 4).
IL-10 is produced by activated Th2 cells, Ly-1 B cells,
monocytes, macrophages, thymocytes, and keratinocytes. It
has pleiotropic effects on a number of different cell types
but in general is notable for its suppressive effects upon cel-
lular activation. For example, one action of IL-10 is to sup-
press the effector functions of macrophages and Th1 cells
by blocking their ability to produce cytokines such as IFN-g,
TNF-a, and IL-2 (40). IL-10–deficient mice raised in a
conventional facility were growth retarded, anemic, and suf-
fered from chronic enterocolitis (42). Mutants kept under
specific pathogen-free conditions had attenuated pheno-
types with a bowel disease limited to the proximal colon,
but still had an iron deficiency anemia, probably reflective
of a degree of malabsorption and of chronic blood loss
through the diseased bowel. The chronic intestinal inflam-
mation seen in IL-10–deficient mice was interpreted as a
disorder in the normal control mechanisms that ordinarily
downregulate responses to mucosal antigens.
Approximately 60% of CRFB42/2 mice kept under con-
ventional conditions developed moderate to severe colitis
without small intestinal involvement, and none developed
severe anemia. There was a slightly lower hemoglobin con-
centration in the CRFB42/2 mice but without any corre-
sponding changes in other red cell values (data not shown).
IL-10–deficient mice did not develop splenomegaly and
had hypoplastic red pulp in the spleen, whereas CRFB42/2
mice typically developed splenomegaly with a hyperprolif-
erative splenic red pulp. Assessing the significance of these
phenotypic differences between IL-10– and CRF2-4–defi-
cient mice would require a side by side histopathologic ex-
amination of the two mutant strains under matched genetic
and environmental conditions.
Functional IL-10 is a homodimer with a tertiary struc-
ture similar to that of IFN-g (44). Binding of IL-10 to cells
that express the IL-10R leads to activation of the Jak1 and
Tyk2 kinases and to tyrosine phosphorylation of Stat3,
which associates with a paired tyrosine domain within the
cytoplasmic receptor region (45). The findings presented
here showing that CRF2-4 is involved in IL-10 signaling,
in conjunction with the report that CRF2-4 can associate
with Tyk2 (25), and with a chimeric IL-10R1 (26), suggest
that a functional IL-10R complex is composed of the IL-
10R1 and CRF2-4, in which IL-10R1 associates with Jak1
and recruits Stat3, and CRF2-4 associates with Tyk2. Thus,
the function of CRF2-4 would be similar to the function
of the IFN-gR2 chain, whose only role is to recruit the
Jak2 kinase into the ligand-assembled receptor complex (46).
Our study raises a number of questions. Since CRF2-4 is
expressed in most human tissues except the brain (data not
shown), whereas IL-10R1 expression is restricted mainly to
human hemopoietic cells and cell lines (5), CRF2-4 may
be shared by other receptor systems, in analogy to other cy-
tokine systems (47, 48). Inversely, whether IL-10R1 and
CRF2-4 alone are sufficient to mediate IL-10 signaling re-
mains to be clarified. However, we believe the data pre-
sented here justify that CRF2-4 be designated IL-10R2.
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